Charcot joint disease, also known as neuropathic arthropathy, is an often underestimated complication related to underlying neurological conditions. In the US, patients with diabetes, especially those with peripheral neuropathy, are at a higher risk for developing Charcot joint disease. The term ‘charcot’ refers to Jean-Martin Charcot, who first described this debilitating condition.
Charcot joint disease manifests through progressive destruction of bones and joints, predominantly affecting the feet and ankles. With charcot, the affected joints become swollen, deformed, and unstable, making daily activities challenging. Early signs of charcot joint disease include warmth, redness, and pain, which can be mistakenly attributed to infection or injury.
Diagnosis relies on clinical examination and imaging. Recognizing charcot early is crucial for preventing severe foot deformities and disability. In the US, podiatric specialists frequently use offloading techniques and immobilization devices as standard treatment for charcot joint disease. Surgical options may be considered for advanced cases.
Living with charcot can impact mobility and quality of life, emphasizing the need for timely intervention and patient education. Awareness campaigns across the US aim to reduce the burden of charcot joint disease, empower patients, and improve outcomes.